CoChat
Sign Up
Cited by 18Retinoids in leukemia and cellular processesAcute Myeloid Leukemia ResearchFlavonoids in Medical Research

All-trans Retinoic Acid in Association with Low Dose Cytosine Arabinoside in the Treatment of Acute Myeoid Leukemia in Elderly Patients

Di Febo, Annalaura, Laurenti, Luca, Falcucci, Paolo, Tosti, Maria Elena, Fianchi, Luana, Pagano, Livio, Leone, Giuseppe·2007·American Journal of Therapeutics
DOI 10.1097/01.mjt.0000208277.65249.52
Open this paper in CoChat — free account

Abstract

All-trans retinoic acid (ATRA) has shown a synergistic activity in combination with cytosine arabinoside in vitro in the treatment of acute myeloid leukaemia (AML). In this paper we report the results of treatment with low dose cytosine arabinoside (LDAC) with or without ATRA in 28 patients with acute myeloid leukaemia aged over 60 years: 14 patients received only LDAC and the other 14 LDAC + ATRA. The patients of the 2 groups showed similar clinical features: in 10 patients AML developed after a myelodysplastic form and 4 patients presented a previous malignancy. All the patients received subcutaneous (sc) LDAC (15 mg twice a day for 14 days) and in 14 patients oral ATRA (45 mg/sqm in the same days) was added to LDAC; the courses were repeated every 4 weeks from diagnosis to relapse. The treatment was well tolerated and the patients could self-administer sc LDAC and oral ATRA at home. No statistically significant differences were observed in complete remission rate (21% vs. 50%, respectively) and resistant rate (57% vs. 29%), but the patients treated with the combination of the 2 drugs had a better time to treatment failure (15 weeks vs. 30 weeks, respectively) (P = 0.045) and a longer survival (37 weeks vs. 66 weeks) (P = 0.019). Our experience, although with a low number of patients, confirms the efficacy of ATRA in combination with sc LDAC in the treatment of AML in elderly patients.

Integrity signals

Registry

Crossref · 10.1097/01.mjt.0000208277.65249.52

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Di Febo et al (2007) found that treatment with low-dose cytosine arabinoside (LDAC) and ATRA lead to an improvement of the time to treatment failure rate and longer survival in patients with AML older than 60 years in comparison with LDAC alone.

    “Di Febo et al (2007) found that treatment with low-dose cytosine arabinoside (LDAC) and ATRA lead to an improvement of the time to treatment failure rate and longer survival in patients with AML older than 60 years in comparison with LDAC alone (Di Febo et al, 2007).”

    From Unlocking the potential of retinoic acid in anticancer therapy (2014) · cites this paper as Di Febo et al, 2007

Cites

Flagged first, then by citations

1 of the 30 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Related

Authors
Di Febo, A., Laurenti, L., Falcucci, P., Tosti, M. E., Fianchi, L., Pagano, L., & Leone, G.
Affiliations
Università Cattolica del Sacro Cuore (IT)
ORCID
Venue
American Journal of Therapeutics
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2007-07
Volume
14
Issue
4
Pages
351-355
ISSN
1075-2765 (ISSN-L)
DOI
10.1097/01.mjt.0000208277.65249.52
OpenAlex
W2046802229
Cited by
18
References
30
Citations by year
2022: 3 · 2021: 2 · 2020: 1 · 2018: 3 · 2017: 1 · 2016: 2 · 2015: 1 · 2014: 1
FWCI
0.40
Type
journal article
Language
en
Open access
closed
Locations
  • American Journal of Therapeutics (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
  • Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
  • Health Sciences › Medicine › Pharmacology › Flavonoids in Medical Research
Keywords
all-trans retinoic acid, acute myeloid leukemia, elderly patients, combination chemotherapy, complete remission, time to treatment failure, survival, myelodysplastic syndrome, oral retinoids
MeSH terms
Acute Disease, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Cytarabine, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Leukemia, Myeloid, Male, Middle Aged, Remission Induction, Tretinoin, Disease-Free Survival, Drug Resistance, Neoplasm

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review